SusannaNaggieMDMHS
Infectious Disease • Durham, NCAssociate Professor, Medicine, Duke University School of Medicine; Director, Infectious Disease Research, Duke Clinical Research Institute; Staff Physician, Durham VA Medical Center
Dr. Naggie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2100 Erwin Rd
Durham, NC 27705Phone+1 919-684-8111
Education & Training
Duke University HospitalFellowship, Infectious Disease, 2007 - 2009- Duke University HospitalResidency, Internal Medicine, 2002 - 2005
Johns Hopkins University School of MedicineClass of 2002
Certifications & Licensure
NC State Medical License 2002 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection Start of enrollment: 2014 May 30
- Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection Start of enrollment: 2019 Nov 15
Publications & Presentations
PubMed
- 39 citationsEffect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.Matthew W McCarthy, Susanna Naggie, David R Boulware, Christopher J Lindsell, Thomas G Stewart
JAMA. 2023-01-24 - 25 citationsExpert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency VirusJordan E. Lake, Turner Overton, Susanna Naggie, Mark S. Sulkowski, Rohit Loomba
Clinical Gastroenterology and Hepatology. 2020-10-16 - 2 citationsFatty Liver Disease: Enter the Metabolic Era.Kara Wegermann, Cynthia Moylan, Susanna Naggie
Current HIV/AIDS Reports. 2023-12-01
Press Mentions
Asthma Drug Did Not Reduce Symptom Duration in Mild to Moderate COVIDOctober 22nd, 2024- Time to Sustained Recovery Among Outpatients with COVID-19 Receiving Montelukast vs PlaceboOctober 18th, 2024
- Higher Dose of Ivermectin, and for Longer, Still No Help Against COVIDFebruary 23rd, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
